World Ophthalmic Pharmaceutical Market 2010-2025
Ophthalmic drugs constitute a prominent segment of the global pharmaceutical market, with sales of over $14bn in 2009. Eye diseases are common worldwide, with expanding patient populations. The recent success of Lucentis highlighted the marked therapeutic and commercial potential of this sector. Which will be the ophthalmic blockbusters of the future? What are the most-promising R&D pipeline developments there? What are the main drivers and restraints for the market? This new report provides answers - and other essential information - to help you understand the ophthalmic pharmaceutical industry and market from 2010 onwards.
World Ophthalmic Pharmaceutical Market 2010-2025 also highlights currently-untreatable and poorly-treated eye diseases with high potential for technological and commercial advances in the foreseeable future. Importantly, you will find out by how much the global ophthalmic market will expand and which countries will achieve rapid sales growth. Sales will be driven by increasing prevalence of ophthalmic disorders among aging populations worldwide. You will also find out where the most-lucrative therapeutic areas of the market will lie from 2010 to 2025.
Ophthalmic market segments covered in this study include:
• Glaucoma
• Retinal disorder
• Dry eye disorder
• Ocular allergies, infections and inflammation.
From 2010 onwards, novel drugs – from small-molecule anti-infectives to complex biotechnological agents – will appear. Those treatments will harness a range of drug delivery systems, with fast-emerging technology. Expected future benefits include restoration of vision and the cessation of vision loss, with high potential gains for developers. From 2010 to 2025, success in the market will be characterised by novel products with superior efficacy, safety and tolerability. World Ophthalmic Pharmaceutical Market 2010-2025 reveals how emerging technologies that increase clinical effectiveness and/or patient compliance will be particularly important therapeutically and commercially.
Detailed analysis of the ophthalmic drug market
World Ophthalmic Pharmaceutical Market 2010-2025 examines that sector critically, through a comprehensive review of information sources, both primary and secondary. This report provides detailed sales forecasts, market share analyses, discussions of pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are 95 tables and figures included, as well as three full interviews with relevant authorities. You will discover a comprehensive market and industry study, one with detailed analyses and informed opinion to benefit your work.
Research interviews from our detailed survey
This report contains interviews with relevant experts:
• Dr Barrett Katz, MD, MBA, Chief Executive Officer and Chief Medical Officer, Danube Pharmaceuticals Inc., New York, USA
• Dr Brian Levy, O.D., MSc, Chief Operating Officer, Danube Pharmaceuticals Inc., New York, USA
• Dr Al Reaves, PhD, Senior Vice President of Clinical Development, Othera Pharmaceuticals Inc., Conshohocken, PA, USA
• Dr Victor Chong, MD, FRCS, FRCOphth, Consultant Ophthalmic Surgeon and Clinical Senior Lecturer in Ophthalmology, University of Oxford and Oxford Eye Hospital, England, UK.
Why you should buy World Ophthalmic Pharmaceutical Market 2010-2025
This report will provide you with the following benefits, in particular:
• You will assess the current market for drug-based treatment of eye disorders
• You will review the overall ophthalmic drug market, including our global sales forecast for 2010 to 2025
• You will receive our sales forecasts for the leading therapy classes from 2010 to 2025, with detailed discussions
• You will receive our sales forecasts for the leading products from 2010 to 2025, with detailed discussions of market potential and competition
• You will obtain a geographical breakdown of relevant sales (US, Japan, leading European markets, India, China and Brazil)
• You will examine commercial drivers and restraints in depth, exploring their significance from 2010 onwards, including a main SWOT analysis
• You will discover the most-exciting R&D pipeline developments, with informed commentary
• You will read expert opinions from our survey of the sector, with full interview transcripts showing forward-looking industrial and academic perspectives
• You will receive discussion of under-met needs in the ophthalmic drugs sector.
This report shows you how the ophthalmic pharmaceutical market will develop worldwide – both technologically and commercially – from 2010 onwards.
Table of Contents
1. Executive Summary
- 1.1 Aims, Scope and Format of the Report
- 1.2 Research Methods
2. Ophthalmic Disorders and Treatments
- 2.1 The Ophthalmology Market
- 2.2 Ophthalmic Disorders
- 2.3 The Human Eye and the Vision Process
- 2.4 Glaucoma
- 2.4.1 Primary Open Angle Glaucoma: The Most Common Type of Glaucoma
- 2.4.2 Closed Angle Glaucoma
- 2.4.3 Secondary Glaucoma
- 2.4.4 Congenital Glaucoma
- 2.4.5 Normal Tension Glaucoma
- 2.4.6 Ocular Hypertension
- 2.4.7 Glaucoma Risk Factors
- 2.4.8 Diagnosis of Glaucoma
- 2.4.9 Prevalence of Glaucoma
- 2.4.10 Treatment of Glaucoma
- 2.4.11 Prostaglandins are the First-Line Treatment of Choice
- 2.4.12 Second-Line Glaucoma Treatments
- 2.4.13 Combination Treatments
- 2.4.14 Laser Treatment
- 2.4.15 Surgery (Trabeculectomy)
- 2.5 Age-Related Macular Degeneration (AMD)
- 2.5.1 Dry AMD
- 2.5.2 Wet AMD
- 2.5.3 AMD Risk Factors
- 2.5.4 Diagnosis of AMD
- 2.5.5 Prevalence of AMD
- 2.5.6 Treatment of AMD
- 2.6 Diabetic Retinopathy
- 2.6.1 Diagnosis of Diabetic Retinopathy
- 2.6.2 Prevalence of Diabetic Retinopathy
- 2.6.3 Laser and Surgical Treatments are the Main Treatments for Diabetic Retinopathy
- 2.6.4 Pharmaceutical Treatments
- 2.7 Ophthalmic Allergies
- 2.7.1 Allergic Conjunctivitis is the Most-Common Eye Allergy
- 2.7.2 Ophthalmic Allergy Treatments
- 2.8 Ophthalmic Inflammatory Disorders
- 2.8.1 Uveitis is the Most Common Ocular Inflammatory Disease
- 2.8.2 Ophthalmic Inflammatory Drugs
- 2.9 Ophthalmic Infections
- 2.9.1 Types of Eye Infection
- 2.9.2 Treatment of Eye Infections
- 2.10 Dry Eye Syndrome
- 2.10.1 Causes and Prevalence of Dry Eye Syndrome
- 2.10.2 The Mainstay of Dry Eye Treatment is Artificial Tears
- 2.10.3 Prescription-Only Drugs for Dry Eye are Limited
- 2.10.4 Tear Augmenters (Punctal Plugs)
3. The Global Ophthalmic Pharmaceutical Market 2010-2025
- 3.1 The Ophthalmic Pharmaceutical Market in 2009
- 3.1.1 Anti-Glaucoma had the Largest Market Share in 2009
- 3.1.2 Top Twenty Ophthalmic Pharmaceutical Brands, 2009
- 3.1.3 Three Manufacturers Account for Almost Half the Market
- 3.2 Global Ophthalmic Pharmaceutical Market Forecasts, 2010-2025
- 3.2.1 Generic Competition in the Ophthalmic Pharmaceutical Market from 2010-2016
- 3.2.2 What are the Prospects for the Ophthalmic Pharmaceutical Market from 2016-2025?
- 3.3 Ophthalmic Pharmaceutical Therapeutic Category Market Forecasts, 2010-2025
- 3.3.1 Retinal Disorders Will Power Growth from 2010-2016
- 3.3.2 Retinal Disorder Drug Growth Will Continue Through 2016-2020
- 3.3.3 High Growth and Return to Market-Leading Position for Anti-Glaucoma Drugs from 2020-2025?
4. The Anti-Glaucoma Market 2010-2025
- 4.1 The Anti-Glaucoma Market in 2009
- 4.1.1 Prostaglandin Analogues Led the Anti-Glaucoma Market in 2009
- 4.1.2 Xalatan
- 4.1.3 Travatan
- 4.1.4 Cosopt
- 4.1.5 Lumigan
- 4.1.6 Alphagan
- 4.1.7 Azopt
- 4.1.8 Xalacom
- 4.1.9 Trusopt
- 4.1.10 Combigan
- 4.2 Anti-Glaucoma Market Forecasts, 2010-2025
- 4.2.1 Generic Competition Will Impact Upon the Anti-Glaucoma Market from 2010-2016
- 4.2.2 Novel Anti-Glaucoma Drugs Will Drive Growth from 2010-2025
- 4.2.3 Xalatan Sales Forecast, 2010-2025
- 4.2.4 Travatan Sales Forecast, 2010-2025
- 4.2.5 Cosopt Sales Forecast, 2010-2025
- 4.2.6 Lumigan Sales Forecast, 2010-2025
- 4.2.7 Alphagan Sales Forecast, 2010-2025
- 4.2.8 Azopt Sales Forecast, 2010-2025
- 4.2.9 Xalacom Sales Forecast, 2010-2025
- 4.2.10 Trusopt Sales Forecast, 2010-2025
- 4.2.11 Combigan Sales Forecast, 2010-2025
5. The Ophthalmic Anti-Allergy/Inflammatory/Infective Market 2010-2025
- 5.1 The Ophthalmic Anti-Allergy/Inflammatory/Infective Market in 2009
- 5.1.1 Patanol
- 5.1.2 Vigamox/Vegamox
- 5.1.3 TobraDex
- 5.1.4 Pataday
- 5.1.5 Acular
- 5.1.6 Cravit
- 5.1.7 Zymar
- 5.2 Ophthalmic Anti-Allergy/Inflammatory/Infective Market Forecasts, 2010-2025
- 5.2.1 Innovation in the Anti-Allergy/Inflammatory/Infective R&D Pipeline
- 5.2.2 Patanol Sales Forecast, 2010-2025
- 5.2.3 Vigamox Sales Forecast, 2010-2025
- 5.2.4 TobraDex Sales Forecast, 2010-2025
- 5.2.5 Pataday Sales Forecast, 2010-2025
- 5.2.6 Acular Sales Forecast, 2010-2025
- 5.2.7 Cravit Sales Forecast, 2010-2025
- 5.2.8 Zymar Sales Forecast, 2010-2025
6. The Retinal Disorder Market 2010-2025
- 6.1 The Retinal Disorder Market in 2009
- 6.1.1 Wet AMD has the Largest Market Share of the Retinal Disorder Market
- 6.1.2 Lucentis Took Control of the Retinal Disorder Market in 2009
- 6.1.3 Visudyne was the Second-Highest-Selling Retinal Disorder Drug in 2009
- 6.1.4 Lucentis has Sidelined Macugen but Faces Potent Threat from Avastin
- 6.2 Retinal Disorder Market Forecasts, 2010-2025
- 6.2.1 Lucentis Will Drive the Retinal Disorder Market from 2010-2016
- 6.2.2 Novel Drugs and New Disease Treatments will Drive Growth from 2016-2025
- 6.2.3 Lucentis Sales Forecast, 2010-2025
- 6.2.4 Visudyne Sales Forecast, 2010-2025
7. The Dry Eye Market 2010-2025
- 7.1 The Dry Eye Market in 2009
- 7.1.1 Restasis is the Only Prescription Drug for Dry Eye in the US
- 7.1.2 Hyalein: Marketed in Japan and China
- 7.1.3 Allergan’s Celluvisc is the Third-Best-Selling Dry Eye Brand
- 7.1.4 The OTC Market for Artificial Tears is Fragmented and Competitive
- 7.2 Dry Eye Market Forecasts, 2010-2025
- 7.2.1 Increased Sales of Dry Eye Prescription Drugs Predicted from 2009-2013
- 7.2.2 Growth in the Dry Eye Market Will Moderate After 2013
- 7.2.3 Restasis Sales Forecast, 2010-2025
- 7.2.4 Hyalein Sales Forecast, 2010-2025
- 7.2.5 Celluvisc Sales Forecast, 2010-2025
8. Issues Affecting the Market for Ophthalmic Pharmaceuticals
- 8.1 SWOT Analysis of the Ophthalmic Pharmaceutical Market
- 8.2 Strengths of the Ophthalmic Pharmaceutical Market
- 8.2.1 Development of New Drug Delivery Methods and Formulations
- 8.2.2 Intraocular Injections
- 8.2.3 Sustained-Release Ocular Implants
- 8.2.4 Gene Therapy and RNA Interference Technology
- 8.2.5 New Ophthalmic Therapeutic Applications for Drugs
- 8.2.6 Development of Neuroprotective Anti-Glaucoma Medications
- 8.3 Weaknesses of the Ophthalmic Pharmaceutical Market
- 8.3.1 The Ophthalmic Pharmaceutical Market Will Face Generic Competition
- 8.3.2 Avastin Cannibalising Lucentis' Revenues?
- 8.4 Opportunities for the Ophthalmic Pharmaceutical Market
- 8.4.1 The Greying of the World Population
- 8.4.2 Increasing Prevalence of Diabetes and Unhealthy Lifestyles
- 8.4.3 Increasing Prevalence of Eye Disorders
- 8.4.4 Retinal Disorders Will Have the Most-Marked Increases in Prevalence
- 8.4.5 Increasing Prevalence of Glaucoma, Dry Eye and Other Ophthalmic Disorders
- 8.4.6 Generous Reimbursement for Ophthalmic Pharmaceuticals
- 8.5 Threats Facing the Ophthalmic Pharmaceutical Market
- 8.5.1 Poor Patient Compliance
- 8.5.2 The Rate of Diagnosis for Many Eye Disorders is Low
9. Ophthalmic Pharmaceutical Country Markets 2010-2025
- 9.1 Leading Ophthalmic Pharmaceutical Country Markets, 2009
- 9.2 Leading Developed Country Ophthalmic Pharmaceutical Markets, 2010-2025
- 9.2.1 The US Ophthalmic Pharmaceutical Market, 2010-2025
- 9.2.2 The Japanese Ophthalmic Pharmaceutical Market, 2010-2025
- 9.2.3 European Ophthalmic Pharmaceutical Markets, 2010-2025
- 9.3 Emerging Economy Ophthalmic Pharmaceutical Market Forecasts, 2010-2025
- 9.3.1 Ophthalmic Pharmaceuticals are Making the Leap to Developing Countries
- 9.3.2 The Chinese Ophthalmic Pharmaceutical Market, 2010-2025
- 9.3.3 The Indian Ophthalmic Pharmaceutical Market, 2010-2025
10. The Ophthalmic Pharmaceutical R&D Pipeline
- 10.1 The Ophthalmic Pharmaceutical Pipeline: Richest in Anti-Glaucoma and Retinal Disorder Drugs
- 10.2 The Anti-Glaucoma Pipeline
- 10.2.1 Neuroprotection Will Be the Most Important Anti-Glaucoma Pipeline Development
- 10.2.2 Taflotan/DE-085 (Santen/Asahi)
- 10.2.3 Azarga (Alcon)
- 10.2.4 Anecortave (Alcon)
- 10.2.5 DNB-001 (Danube)
- 10.2.6 BVT.28949 (Biovitrum)
- 10.2.7 OT-730 (Othera)
- 10.2.8 AL-37807 (Alcon)
- 10.2.9 PF-4217329 (Pfizer)
- 10.2.10 QLT's Punctal Plug Delivery Technology
- 10.2.11 PF-03187207 (NicOx/Pfizer)
- 10.3 The Ophthalmic Anti-Allergy Pipeline
- 10.3.1 Bepreve (ISTA/Senju)
- 10.3.2 FOV1101 (Fovea/CombinatoRx)
- 10.3.3 DE-103 (Santen)
- 10.4 The Ophthalmic Anti-Inflammatory Pipeline
- 10.4.1 T-Pred (ISTA)
- 10.4.2 AzaSite Plus/ASV-502 (InSite Vision)
- 10.4.3 Durezol (Senju/Sirion Therapeutics)
- 10.4.4 Luveniq (Lux Biosciences)
- 10.4.5 Simulect (Cerimon)
- 10.4.6 EGP-437 (EyeGate Pharm)
- 10.5 The Ophthalmic Anti-Infective Pipeline
- 10.5.1 TobraDex ST (Alcon)
- 10.5.2 ISV-403/Besifloxacin (Bausch & Lomb)
- 10.5.3 Moxifloxacin/Dexamethasone (Alcon)
- 10.5.4 Aganocide (Alcon/NovaBay)
- 10.6 The Retinal Disease Pipeline
- 10.6.1 Retinal Diseases Have the Richest Pipeline
- 10.6.2 Arxxant (Eli Lilly/Alcon/Takeda)
- 10.6.3 Vitrase/Vitragen (ISTA)
- 10.6.4 Aflibercept/VEGF Trap-Eye (Regeneron/Bayer)
- 10.6.5 Bevasiranib/Cand5 (Opko)
- 10.6.6 Atacand/TCV-116 (AstraZeneca/Takeda)
- 10.6.7 Medidur (pSivida/Alimera Sciences/Pfizer)
- 10.6.8 NT-501 (Neurotech)
- 10.6.9 Microplasmin (ThromboGenics)
- 10.6.10 Sustained-Release Brimonidine (Allergan)
- 10.6.11 RTP801i-14/PF-4523655 (Quark/Pfizer)
- 10.6.12 AGN-745/SIRNA-027 (Allergan/Merck & Co.)
- 10.6.13 ATG-3 (CoMentis)
- 10.6.14 OT-551 (Othera)
- 10.6.15 Fenretinide (Sirion Therapeutics)
- 10.6.16 RPE65 Gene Therapy (Targeted Genetics)
- 10.7 The Dry Eye Pipeline
- 10.7.1 Prolacria (Inspire/Allergan/Santen)
- 10.7.2 Cyclosporine Ophthalmic Solution (Sirion Therapeutics)
- 10.7.3 Rebamipide (Otsuka/Acucela)
- 10.7.4 DE-101/Rivoglitazone (Santen)
- 10.7.5 Ecabet (ISTA)
- 10.7.6 SAR 1118 (SARcode)
- 10.8 The Pipeline for Other Ophthalmic Indications Includes Eyelash Growth Stimulators
11. Expert Views from Key Opinion Leaders
- 11.1 Barrett Katz, MD, MBA, Chief Executive Officer and Chief Medical Officer and Brian Levy, O.D., MSc, Chief Operating Officer, Danube Pharmaceuticals Inc., New York, USA
- 11.1.1 Neuroprotection is the Key Unmet Need Among Glaucoma Patients
- 11.1.2 Danube's Pipeline Anti-Glaucoma Medication: DNB-001
- 11.1.3 Key Threats Facing the Ophthalmic Pharmaceutical Industry
- 11.1.4 Major Growth Opportunities in the Ophthalmic Pharmaceutical Industry
- 11.1.5 The Future of the Anti-Glaucoma Market
- 11.2 Dr Al Reaves, PhD, Senior Vice President of Clinical Development, Othera Pharmaceuticals Inc., Conshohocken, PA, USA
- 11.2.1 Which Areas of the Ophthalmic Pharmaceutical Market will Experience Greatest Growth?
- 11.2.2 Othera's Geographic Atrophy Drug: OT-551
- 11.2.3 How Will Glaucoma be Treated in 2025?
- 11.2.4 Othera's Neuroprotective Anti-Glaucoma Drug: OT-440
- 11.2.5 Othera's New Generation Beta Blocker: OT-730
- 11.2.6 New Drugs for Ophthalmic Conditions Currently with No Treatments
- 11.3 Dr Victor Chong, MD, FRCS, FRCOphth, Consultant Ophthalmic Surgeon and Clinical Senior Lecturer in Ophthalmology, University of Oxford, Oxford Eye Hospital, England, UK
- 11.3.1 Key Unmet Needs
- 11.3.2 Research and Development
- 11.3.3 Problems with the Current Use of Ophthalmic Treatments
- 11.3.4 Challenges in the Development of Ophthalmic Drugs
- 11.3.5 Complexities Involved in Developing New Ophthalmic Drugs
- 11.3.6 Growth Opportunities in the Ophthalmic Market
- 11.3.7 Challenges Facing the Ophthalmic Pharma Industry
- 11.3.8 Main Regions Offering Growth Potential Worldwide
- 11.3.9 Needs of Glaucoma Patients
- 11.3.10 Future Treatments for Glaucoma
- 11.3.11 Pipeline Developments from a Physician's Perspective
- 11.3.12 Prospects for Replacing Current Treatments
- 11.3.13 Novel Treatments for Ophthalmic Diseases
12. Conclusions
- 12.1 The Ophthalmic Pharmaceutical Market in 2009
- 12.2 Ophthalmic Pharmaceutical Market Forecast, 2010-2025
- 12.3 Who Will Succeed in the Ophthalmic Pharmaceutical Market?
- 12.4 Where Will the Ophthalmic Pharmaceutical Market Grow Fastest?
Lists of Tables
- Table 2.1 Glaucoma Drug Types, 2009
- Table 2.2 AMD Drug Types, 2009
- Table 2.3 Ophthalmic Allergy Drug Types, 2009
- Table 2.4 Ophthalmic Inflammatory Disorder Drug Types, 2009
- Table 2.5 Ophthalmic Anti-Infective Drug Types, 2009
- Table 3.1 Ophthalmic Pharmaceutical Therapeutic Category Market Shares, 2009
- Table 3.2 Top Twenty Ophthalmic Pharmaceutical Brands, 2009
- Table 3.3 Top Ten Ophthalmic Pharmaceutical Manufacturers, 2009
- Table 3.4 World Ophthalmic Pharmaceutical Market Sales Forecast, 2010-2016
- Table 3.5 World Ophthalmic Pharmaceutical Market Sales Forecast, 2017-2025
- Table 3.6 Ophthalmic Pharmaceutical Therapeutic Category Forecasts, 2010-2016
- Table 3.7 Ophthalmic Pharmaceutical Therapeutic Category Forecasts, 2017-2025
- Table 4.1 Leading Anti-Glaucoma Brands, 2009
- Table 4.2 World Anti-Glaucoma Market Sales Forecast, 2010-2016
- Table 4.3 World Anti-Glaucoma Market Sales Forecast, 2017-2025
- Table 4.4 Leading Anti-Glaucoma Brands Sales Forecasts, 2010-2016
- Table 4.5 Leading Anti-Glaucoma Brands Sales Forecasts, 2017-2025
- Table 5.1 Therapeutic Category Market Shares in the Ophthalmic Anti- Allergy/Inflammatory/Infective Market, 2009
- Table 5.2 Leading Anti-Allergy/Inflammatory/Infective Brands, 2009
- Table 5.3 Ophthalmic Anti-Allergy/Inflammatory/Infective Market Sales Forecast, 2010-2016
- Table 5.4 Ophthalmic Anti-Allergy/Inflammatory/Infective Market Sales Forecast, 2017-2025
- Table 5.5 Leading Anti-Allergy/Inflammatory/Infective Brand Sales Forecasts, 2010-2016
- Table 5.6 Leading Anti-Allergy/Inflammatory/Infective Brand Sales Forecasts, 2017-2025
- Table 6.1 Therapeutic Category Market Shares in the Retinal Disorder Market, 2009
- Table 6.2 Leading Retinal Disorder Brands, 2009
- Table 6.3 World Retinal Disorder Market Sales Forecast, 2010-2016
- Table 6.4 World Retinal Disorder Market Sales Forecast, 2017-2025
- Table 6.5 Leading Retinal Disorder Brands Sales Forecast, 2010-2016
- Table 6.6 Leading Retinal Disorder Brands Sales Forecast, 2017-2025
- Table 7.1 Leading Dry Eye Brands, 2009
- Table 7.2 World Dry Eye Market Sales Forecast, 2010-2016
- Table 7.3 World Dry Eye Market Sales Forecast, 2017-2025
- Table 7.4 Restasis Sales Forecast, 2010-2016
- Table 7.5 Restasis Sales Forecast, 2017-2025
- Table 7.6 Hyalein Sales Forecast, 2010-2016
- Table 7.7 Hyalein Sales Forecast, 2017-2025
- Table 7.8 Celluvisc Sales Forecast, 2010-2016
- Table 7.9 Celluvisc Sales Forecast, 2017-2025
- Table 8.1 SWOT Analysis of the Ophthalmic Pharmaceutical Market, 2010-2025
- Table 8.2 Expected Patent Expiries for Leading Ophthalmic Pharmaceuticals, 2009-2014
- Table 8.3 Global Ophthalmic Disorder Prevalence Forecast, 2007-2030
- Table 9.1 Leading Ophthalmic Pharmaceutical Country Markets, 2009
- Table 9.2 Leading Ophthalmic Pharmaceutical Country Market Sales Forecasts, 2010-2016
- Table 9.3 Leading Ophthalmic Pharmaceutical Country Market Sales Forecasts, 2017-2025
- Table 10.1 Key Drugs in the Anti-Glaucoma Pipeline, 2009
- Table 10.2 Key Drugs in the Ophthalmic Anti-Allergy Pipeline, 2009
- Table 10.3 Key Drugs in the Ophthalmic Anti-Inflammatory Pipeline, 2009
- Table 10.4 Key Drugs in the Ophthalmic Anti-Infective Pipeline, 2009
- Table 10.5 Key Drugs in the Retinal Disease Pipeline, 2009
- Table 10.6 Key Drugs in the Dry Eye Pipeline, 2009
- Table 10.7 Key R&D Pipeline Drugs for Other Ophthalmic Indications, 2009
Lists of Figures
- Figure 3.1 Ophthalmic Pharmaceutical Therapeutic Category Market Shares, 2009
- Figure 3.2 Top Ten Ophthalmic Pharmaceutical Manufacturers, 2009
- Figure 3.3 World Ophthalmic Pharmaceutical Market Sales Forecast, 2010-2025
- Figure 3.4 Ophthalmic Pharmaceutical Therapeutic Category Market Shares and Sales Forecasts, 2010-2025
- Figure 3.5 Ophthalmic Pharmaceutical Therapeutic Category Sales Forecasts, 2010-2025
- Figure 4.1 Leading Anti-Glaucoma Brands, 2009
- Figure 4.2 World Anti-Glaucoma Market Sales Forecast, 2010-2025
- Figure 4.3 Leading Anti-Glaucoma Brands, 2016
- Figure 4.4 Xalatan Sales Forecast, 2010-2025
- Figure 4.5 Travatan Sales Forecast, 2010-2025
- Figure 4.6 Cosopt Sales Forecast, 2010-2025
- Figure 4.7 Lumigan Sales Forecast, 2010-2025
- Figure 4.8 Alphagan Sales Forecast, 2010-2025
- Figure 4.9 Azopt Sales Forecast, 2010-2025
- Figure 4.10 Xalacom Sales Forecast, 2010-2025
- Figure 4.11 Trusopt Sales Forecast, 2010-2025
- Figure 4.12 Combigan Sales Forecast, 2010-2025
- Figure 5.1 Therapeutic Category Market Shares in the Ophthalmic Anti- Allergy/Inflammatory/Infective Market, 2009
- Figure 5.2 Ophthalmic Anti-Allergy/Inflammatory/Infective Market Sales Forecast, 2010-2025
- Figure 5.3 Patanol Sales Forecast, 2010-2025
- Figure 5.4 Vigamox Sales Forecast, 2010-2025
- Figure 5.5 TobraDex Sales Forecast, 2010-2025
- Figure 5.6 Pataday Sales Forecast, 2010-2025
- Figure 5.7 Acular Sales Forecast, 2010-2025
- Figure 5.8 Cravit Sales Forecast, 2010-2025
- Figure 5.9 Zymar Sales Forecast, 2010-2025
- Figure 6.1 Therapeutic Category Market Shares in the Retinal Disorder Market, 2009
- Figure 6.2 Leading Retinal Disorder Brands, 2009
- Figure 6.3 World Retinal Disorder Market Sales Forecast, 2010-2025
- Figure 6.4 Lucentis Sales Forecast, 2010-2025
- Figure 6.5 Visudyne Sales Forecast, 2010-2025
- Figure 7.1 World Dry Eye Market Sales Forecast, 2010-2025
- Figure 7.2 Restasis Sales Forecast, 2010-2025
- Figure 7.3 Hyalein Sales Forecast, 2010-2025
- Figure 7.4 Celluvisc Sales Forecast, 2010-2025
- Figure 8.1 Global Population Aged Over 65, 2010-2025
- Figure 8.2 Population Aged 65 Years or Over in Major Ophthalmic Pharmaceutical Country Markets, 2009 and 2025
- Figure 8.3 Global Prevalence of Diabetes and Diabetic Retinopathy, 2007 and 2030
- Figure 9.1 Leading Ophthalmic Pharmaceutical Country Markets, 2009
- Figure 9.2 Leading Ophthalmic Pharmaceutical Country Markets, 2015
- Figure 9.3 Leading Ophthalmic Pharmaceutical Country Markets, 2020
- Figure 9.4 Leading Ophthalmic Pharmaceutical Country Markets, 2025
- Figure 9.5 US and Japanese Ophthalmic Pharmaceutical Market Sales Forecasts, 2010-2025
- Figure 9.6 European, Brazilian, Indian and Chinese Ophthalmic Pharmaceutical Market Sales Forecasts, 2010-2025
- Figure 12.1 World Ophthalmic Pharmaceutical Market Sales Forecast, 2010-2025
Other users found this report page using the following search terms: Ophthalmic market ophthalmic 2010 sales pharmaceutical world glaucoma uk growth drug
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.
Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.